Evidence map›Paper›PMID 29330502›Full record

ArticleScientific reports2018

Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression.

Berline Murekatete, Ali Shokoohmand, Jacqui McGovern, Lipsa Mohanty, Christoph Meinert, Brett G Hollier, Alfred Zippelius, Zee Upton, Abhishek S Kashyap

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Dormancy of cutaneous melanoma.Cancer cell international · 2024
    Review
  4. Review
  5. Review
  6. Proteinaceous Hydrogels for Bioengineering Advanced 3D Tumor Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Research in pharmaceutical sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Berline MurekateteInstitute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Brisbane, QLD, Australia.
Ali ShokoohmandInstitute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Brisbane, QLD, Australia.
Jacqui McGovernInstitute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0002-4993-6745
Lipsa MohantyInstitute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Brisbane, QLD, Australia.
Christoph MeinertInstitute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Brisbane, QLD, Australia.
Brett G HollierAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Queensland, Australia.
Alfred ZippeliusCancer Immunology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Zee UptonInstitute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Brisbane, QLD, Australia.
Abhishek S KashyapInstitute of Health and Biomedical Innovation, School of Biomedical Science, Queensland University of Technology, Brisbane, QLD, Australia. abhishek.kashyap@unibas.ch.
Queensland University of Technology · AUTranslational Research Institute · AUAgency for Science, Technology and Research · SGUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin-like growth factor (IGF)-I binds to the ECM protein vitronectin (VN) through IGF binding proteins (IGFBPs) to enhance proliferation and migration of skin keratinocytes and fibroblasts. Although evidence exists for the role of individual components of the complex (IGF-I, IGFBP-3 and VN), the cellular functions stimulated by these proteins together as a complex remains un-investigated in melanoma cells. We report here that the IGF-I:IGFBP-3:VN trimeric complex stimulates a dose-dependent increase in the proliferation and migration of WM35 and Sk-MEL28 melanoma cells. In 3D Matrigel

Indexed as

Carcinoma, Squamous CellCell Culture TechniquesCell Line, TumorCell MovementCell ProliferationDisease ProgressionExtracellular MatrixHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMelanomaMultiprotein ComplexesProtein BindingVitronectinIGF1 protein, humanIGFBP3 protein, humanInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMultiprotein ComplexesVitronectin

Identifiers

PMID29330502
PMCPMC5766529
OpenAlexW2784147673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.